Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1991 May;63(5):799–803. doi: 10.1038/bjc.1991.177

Prognostic role of amenorrhea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer.

A R Bianco 1, L Del Mastro 1, C Gallo 1, F Perrone 1, E Matano 1, C Pagliarulo 1, S De Placido 1
PMCID: PMC1972375  PMID: 2039706

Abstract

The prognostic role of drug-induced amenorrhea (DIA) was restrospectively evaluated in 221 out of 254 consecutive premenopausal patients treated with adjuvant CMF or a CMF-containing regimen; 33 patients were eliminated because of lack of menstrual data. All patients had metastatic axillary nodes; drug regimens were: CMF x 9 courses +/- Tamoxifen (TM) and CMF x 6 courses; median age was 43 (range 26-54). Premenopausal status was defined as last normal menses within the 6 weeks preceding initiation of chemotherapy: DIA as cessation of menses for at least 3 months not later than 3 months from the end of chemotherapy. DIA occurred in 166,221 (75.1%) patients and was strictly related to the age of the patients; also, the older the patients the shorter the time required to develop DIA. At median follow up of 69 months, Mantel-Byar analysis showed a longer disease free survival (DFS) for patients who developed DIA as compared with non amenorrheic women (P less than 0.001). DIA prognostic value was independent of age, number of involved nodes, tumour size and number of CMF cycles, as assessed by the Cox model (RH 0.43, 95% C.I. 0.24-0.77), in which DIA was entered as a time dependent covariate.

Full text

PDF
799

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson J. R., Cain K. C., Gelber R. D. Analysis of survival by tumor response. J Clin Oncol. 1983 Nov;1(11):710–719. doi: 10.1200/JCO.1983.1.11.710. [DOI] [PubMed] [Google Scholar]
  2. Bianco A. R., De Placido S., Gallo C., Pagliarulo C., Marinelli A., Petrella G., D'Istria M., Delrio G. Adjuvant therapy with tamoxifen in operable breast cancer. 10 year results of the Naples (GUN) study. Lancet. 1988 Nov 12;2(8620):1095–1099. [PubMed] [Google Scholar]
  3. Brincker H., Rose C., Rank F., Mouridsen H. T., Jakobsen A., Dombernowsky P., Panduro J., Andersen K. W. Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer. J Clin Oncol. 1987 Nov;5(11):1771–1778. doi: 10.1200/JCO.1987.5.11.1771. [DOI] [PubMed] [Google Scholar]
  4. Bryant A. J., Weir J. A. Prophylactic oophorectomy in operable instances of carcinoma of the breast. Surg Gynecol Obstet. 1981 Nov;153(5):660–664. [PubMed] [Google Scholar]
  5. Fisher B., Sherman B., Rockette H., Redmond C., Margolese R., Fisher E. R. 1-phenylalanine mustard (L-PAM) in the management of premenopausal patients with primary breast cancer: lack of association of disease-free survival with depression of ovarian function. National Surgical Adjuvant Project for Breast and Bowel Cancers. Cancer. 1979 Sep;44(3):847–857. doi: 10.1002/1097-0142(197909)44:3<847::aid-cncr2820440309>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  6. Goldhirsch A., Gelber R. D., Castiglione M. The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. The International Breast Cancer Study Group. Ann Oncol. 1990;1(3):183–188. doi: 10.1093/oxfordjournals.annonc.a057718. [DOI] [PubMed] [Google Scholar]
  7. Koyama H., Wada T., Nishizawa Y., Iwanaga T., Aoki Y. Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer. 1977 Apr;39(4):1403–1409. doi: 10.1002/1097-0142(197704)39:4<1403::aid-cncr2820390408>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  8. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966 Mar;50(3):163–170. [PubMed] [Google Scholar]
  9. Nissen-Meyer R. The role of prophylactic castration in the therapy of human mammary cancer. Eur J Cancer. 1967 Nov;3(4):395–403. doi: 10.1016/0014-2964(67)90024-2. [DOI] [PubMed] [Google Scholar]
  10. Padmanabhan N., Howell A., Rubens R. D. Mechanism of action of adjuvant chemotherapy in early breast cancer. Lancet. 1986 Aug 23;2(8504):411–414. doi: 10.1016/s0140-6736(86)92131-8. [DOI] [PubMed] [Google Scholar]
  11. Padmanabhan N., Wang D. Y., Moore J. W., Rubens R. D. Ovarian function and adjuvant chemotherapy for early breast cancer. Eur J Cancer Clin Oncol. 1987 Jun;23(6):745–748. doi: 10.1016/0277-5379(87)90272-0. [DOI] [PubMed] [Google Scholar]
  12. Rose D. P., Davis T. E. Effects of adjuvant chemohormonal therapy on the ovarian and adrenal function of breast cancer patients. Cancer Res. 1980 Nov;40(11):4043–4047. [PubMed] [Google Scholar]
  13. Simon R., Makuch R. W. A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias. Stat Med. 1984 Jan-Mar;3(1):35–44. doi: 10.1002/sim.4780030106. [DOI] [PubMed] [Google Scholar]
  14. Tormey D. C., Gray R., Gilchrist K., Grage T., Carbone P. P., Wolter J., Woll J. E., Cummings F. J. Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients. An Eastern Cooperative Oncology Group trial. Cancer. 1990 Jan 15;65(2):200–206. doi: 10.1002/1097-0142(19900115)65:2<200::aid-cncr2820650203>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES